Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single‑center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database

• Published in: Oncology letters 2020-10, Vol.20 (4), p.1-1
• Main Authors: Yang, Hong, Wang, Rong, Zeng, Furen, Zhao, Jie, Peng, Shunli, Ma, Yueyun, Chen, Shiyu, Ding, Sijie, Zhong, Longhui, Guo, Wei, Wang, Wei
• Format: Article
• Language: English
• Subjects: Analysis; Breast cancer; Cancer metastasis; Cancer research; Cohort analysis; Datasets; Epidemiology; Gene amplification; Liver; Lymphatic system; Medical prognosis; Metastasis; Oncology; Patient outcomes; Surveillance
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2020.11948

Breast cancer is a highly heterogeneous disease at the molecular level and >90% of mortalities are due to metastasis and its associated complications. The present study determined the impact of molecular subtypes on metastatic behavior and overall survival (OS) of patients with metastatic breast cancer. The influence of molecular subtypes on the sites and number of metastases in 166 patients with metastatic breast cancer from a single center were assessed; and the influence of molecular subtypes on the sites and number of metastases and OS in 15,322 metastatic cases among 329,770 patients with primary breast cancer from the Surveillance, Epidemiology and End Results database were assessed. Analysis of both datasets revealed that different molecular subtypes exhibited differences in the prevalence of different metastatic sites and number of metastases. A larger proportion of bone metastasis was observed in the hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)+ subtype than in other subtypes, more lung metastasis was observed in the HR-/[HER2.sup.+] subtype and more liver metastasis occurred in the [HR.sup.+]/[HER2.sup.+] and HR-/[HER2.sup.+] subtypes. Single-site metastasis was more common for the [HR.sup.+]/HER2- subtype than in other subtypes, while 2-3 sites of metastases were more common for the [HR.sup.+]/[HER2.sup.+] subtype and >4 sites of metastases were more frequent in the HR-/[HER2.sup.+] and HR-/HER2- subtypes. The mean OS of patients with primary breast cancer in the [HR.sup.+]/HER2- subtype group was the longest (78.5 months), while the HR-/HER2- group had the shortest mean OS (69.1 months). The mean OS of the metastatic [HR.sup.+]/[HER2.sup.+] group was the longest (46.0 months), while the mean OS of the metastatic HR-/HER2- group was the shortest (18.5 months). In conclusion, the results of the present study suggested that different molecular subtypes of breast cancer have different metastatic behavior, as well as mean OS.